金融界6月25日消息，上证指数低开高走，中证沪深港生物科技主题指数 (沪深港生物科技主题， 932245)报1352.64点。 资料显示，指数样本每半年调整一次，样本调整实施时间分别为每年6月和12月的第二个星期五的下一 交易日。权重因子随样本定期调整而调整，调整时间与指数样本定期调整实施时间相同。在下一个定期 调整日前，权重因子一般固定不变。当特殊情况下将对指数进行临时调整。当样本退市时，将其从指数 样本中剔除。样本公司发生收购、合并、分拆等情形的处理，参照计算与维护细则处理。当沪股通、深 股通和港股通证券范围发生变动导致样本不再满足互联互通资格时，指数将相应调整。 本文源自：金融界 作者：行情君 从指数持仓来看，中证沪深港生物科技主题指数十大权重分别为：恒瑞医药（12.02%）、百济神州 （10.82%）、药明康德（8.63%）、迈瑞医疗（7.04%）、信达生物（6.24%）、药明生物（4.88%）、 康方生物（3.31%）、石药集团（3.04%）、中国生物制药（2.78%）、三生制药（2.05%）。 从中证沪深港生物科技主题指数持仓的市场板块来看，香港证券交易所占比45.80%、上海证券交易所 占比33 ...

Group 1 - The core viewpoint of the news is the launch of the Shanghai Stock Exchange Science and Technology Innovation Board Computer Theme Index, which adds to the growing number of A-share indices, reaching 402 this year, a 24.01% increase year-on-year [1] - The development of the index system is guided by policies such as the "Action Plan for Promoting High-Quality Development of Index Investment in Capital Markets," which aims to enhance the quality and diversity of index offerings [1][2] - The A-share market has seen a significant increase in the number of new indices, particularly in the bond category, with 154 new bond indices launched this year, marking a 42.59% increase compared to the previous year [2] Group 2 - The new indices reflect a deep alignment with national development strategies, focusing on sectors like biotechnology and semiconductors, which are part of the "new quality productivity" strategy [3] - The index compilation logic has become more refined, emphasizing "theme deepening + scenario segmentation," allowing for a more precise capture of micro-level industry upgrades [3] - Future index product innovations are expected to accelerate, expanding from broad-based indices to more specialized thematic indices and incorporating a wider range of asset classes [4] Group 3 - The structural optimization of A-share indices is closely tied to national strategies, with a clear framework established by the China Securities Regulatory Commission's "Action Plan" [5] - Since the release of the "Action Plan," 114 new ETF products have been launched by 35 fund companies, indicating a robust response from market participants [5] - Collaborative efforts, such as the partnership between Shenzhen Securities Information Co. and Hang Seng Indexes, aim to create cross-border investment indices to meet investor needs [6] Group 4 - The initiatives are transforming the index investment ecosystem from a "single product supply" model to a "full-chain capability building" approach, fostering a positive cycle of policy guidance, market response, and ecological feedback [7] - Index investment is positioned as a foundational element driving high-quality development in the capital market, serving not only as an investment tool but also as a means to support national strategies [7]

Group 1 - The core viewpoint of the article highlights the performance of the CSI Hong Kong-Shanghai Biotech Theme Index, which reflects the overall performance of listed companies in the biotech sector from mainland China and Hong Kong [1][3] - The CSI Hong Kong-Shanghai Biotech Theme Index has shown an increase of 0.82% over the past month, 12.93% over the past three months, and 12.21% year-to-date [1] - The index consists of 50 sample companies involved in biopharmaceuticals, pharmaceuticals, and biotech services, with a base date of December 28, 2018, set at 1000.0 points [1] Group 2 - The top ten weighted companies in the index include: Heng Rui Medicine (13.16%), BeiGene (10.43%), WuXi AppTec (8.41%), Mindray Medical (7.71%), WuXi Biologics (5.15%), Innovent Biologics (4.82%), CanSino Biologics (3.91%), Shanghai Pharmaceuticals (2.74%), China National Pharmaceutical Group (2.45%), and Shanghai RAAS Blood Products (1.83%) [1] - The market share of the index holdings is distributed as follows: Hong Kong Stock Exchange 41.72%, Shanghai Stock Exchange 35.62%, and Shenzhen Stock Exchange 22.66% [1] Group 3 - In terms of industry composition, biopharmaceuticals account for 43.26%, chemical drugs for 25.78%, pharmaceutical and biotech services for 21.39%, and medical devices for 9.57% [2] - The index samples are adjusted semi-annually, with adjustments occurring on the next trading day after the second Friday of June and December each year [2] - Special circumstances may lead to temporary adjustments to the index, including the removal of samples that are delisted or changes due to mergers, acquisitions, or other corporate actions [2]